Does Prozac (fluoxetine) help with hot flashes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fluoxetine for Hot Flashes

Fluoxetine can help reduce hot flashes with a modest effect, decreasing hot flash composite scores by approximately 50% compared to 36% with placebo, though there is significant variability in individual response. 1

Efficacy of Fluoxetine for Hot Flashes

Fluoxetine has been studied specifically for menopausal hot flashes with the following results:

  • In breast cancer patients, fluoxetine decreased hot flash composite score by 50% versus 36% for placebo 1
  • Response to fluoxetine varies considerably:
    • 42% of women improve by >50%
    • 30% improve by <50%
    • 27% may experience worsening hot flashes 1
  • Long-term efficacy is questionable - one study reported that at 9 months, fluoxetine was not superior to placebo for vasomotor symptoms 1, 2
  • When directly compared to gabapentin in a crossover study, gabapentin 300 mg/day was more effective than fluoxetine 20 mg/day for treating vasomotor symptoms 3

Dosing and Administration

  • For hot flashes, lower doses are typically used than for depression 1
  • The response to SSRIs for hot flashes is typically faster than when used for depression 1
  • When discontinuing fluoxetine, gradual tapering is recommended to minimize withdrawal symptoms 1

Side Effects and Considerations

Common side effects include:

  • Headache
  • Nausea
  • Reduced appetite
  • Gastrointestinal disturbance
  • Dry mouth
  • Anxiety/agitation
  • Sleep disturbance
  • Sexual dysfunction 1

Most side effects are mild and short-lived, but adverse events cause 10-20% of individuals to withdraw from treatment 1.

Special Considerations with Tamoxifen

Important caution: Fluoxetine is a potent inhibitor of CYP2D6 enzyme and may interfere with the breakdown of tamoxifen to its active metabolite endoxifen 1. This interaction could potentially reduce tamoxifen's effectiveness in breast cancer patients.

  • For women taking tamoxifen, alternative SSRIs/SNRIs with less impact on CYP2D6 (such as citalopram or venlafaxine) are preferred 1
  • The NCCN recommends alternative therapy if available for patients on tamoxifen 1

Alternative Options for Hot Flash Management

If fluoxetine is not effective or contraindicated, consider:

  1. Other SSRIs/SNRIs:

    • Venlafaxine (75 mg is optimal dose) - 61% reduction in hot flash score 1
    • Paroxetine (10 mg or 12.5 mg CR) - 62-65% reduction 1
    • Citalopram - may be effective for those who don't respond to venlafaxine 1
    • Desvenlafaxine - 64% reduction in hot flashes at 12 weeks 1
  2. Non-SSRI medications:

    • Gabapentin - decreased hot flash severity score by 46% at 8 weeks compared with 15% reduction in placebo 1
    • Clonidine - can reduce hot flash frequency and severity 1
  3. Non-pharmacologic approaches:

    • Acupuncture - shown to be safe and effective in several studies 1
    • Yoga - may improve quality of life associated with menopause 1
    • Lifestyle modifications and weight loss if overweight 1

Clinical Decision Algorithm

  1. First-line options:

    • For women NOT on tamoxifen: Venlafaxine, paroxetine, or fluoxetine
    • For women on tamoxifen: Venlafaxine or citalopram (to avoid CYP2D6 inhibition)
  2. If first-line fails or is not tolerated:

    • Try gabapentin (especially if sleep disturbance is a major issue)
    • Consider clonidine (though side effects may limit use)
  3. If pharmacologic options fail:

    • Consider non-pharmacologic approaches like acupuncture

Remember that the overall clinical efficacy of antidepressants for hot flashes appears modest compared to estrogen therapy, though direct head-to-head studies are limited 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A crossover study comparing gabapentin and fluoxetine for the treatment of vasomotor symptoms among postmenopausal women.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.